Molecular genetic studies of glial tumors in children
https://doi.org/10.24884/1607-4181-2016-23-4-49-53
Abstract
Glioblastomas are the most frequent malignant neoplasm among primary brain tumors of childhood. Despite the advances in a multimodality treatment approach including neurosurgery, radiotherapy and chemotherapy, the overall survival of such patients remains poor and doesn’t exceed 14 months. The using of targeted agents such as gefitinib in unselected patient populations showed insufficient efficacy. Nowadays, the most perspective approach is a selection of patient populations potentially sensitive to targeted therapy based on predictive markers of response. We performed a comprehensive analysis of the mutational patterns in 30 glioblastomas of children. Data Analysis was based on the new method of mass spectrometry (OncoCarta v1.0, Sequenom) that enabled us to estimate 298 mutations in 19 genes and to identify 10 mutations in 9 tumors (30 %). Mutations were found in BRAF, CDK, HRAS, EGFR, FGFR, MET and PI3K. The most mutated pathway was EGFR – in 20 % of the samples (6/30). The obtained results seem to be very promising in terms of possibilities of using new targeted agents including BRAF inhibitors for treatment of children with glial brain tumors.
About the Authors
P. S. Soltan
LLC “BioVitrum” (68, Bolshoy Prosp. of Vasilievsky Island, 199178, Russia)
Russian Federation
Russian Federation
F. V. Moiseenko
St. Petersburg’s national research academic university of Russian academy of sciences (8/3, Khlopina Str., St. Petersburg, 194021, Russia)
Russian Federation
Russian Federation
V. N. Ochkolyas
Academician I.P. Pavlov First St. Petersburg State Medical University (6-8, L. Tosltoy Str., St. Petersburg, 197022, Russia)
V. Yu. Startsev
St. Petersburg’s State Pediatric Medical University (2, Lytovskaya Str., St. Petersburg, 194100, Russia)
Russian Federation
Russian Federation
References
1. Bentley D. R. et al. Accurate whole human genome sequencing using reversible terminator chemistry // Nature. – 2008. – № 456 (7218). – P. 53–59.
2. Cerami A. et al. Automated network analysis identifies core pathways in glioblastoma // PLoS One. – 2010. – № 5 (2). – P. e8918.
3. Comprehensive genomic characterization defines human glioblastoma genes and core pathways / TCGA // Nature. – 2008. – № 455 (7216). – P. 1061–1068.
4. Engelman J. A., LuoJ., CantleyL. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism // Nat. Rev. Genet. – 2006. – № 7 (8). – P. 606–619.
5. Ford J. M. et al. Results of the phase I doseescalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastomamultiforme // Int. J. Radiat. Oncol. Biol. Phys. – 2007. – № 69 (3). – P. 831–838.
6. Forshew T. et al. Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocyticastrocytomas // J. Pathol. – 2009. – № 218 (2). – P. 172–181.
7. Gymnopoulos M., Elsliger M. A., Vogt P. K. Rare cancerspecific mutations in PIK3CA show gain of function // Proc. Natl. Acad. Sci. USA. – 2007. – № 104 (13). – P. 5569–5574.
8. Idbaih A. et al. Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma // Neuropathol. Appl. Neurobiol. – 2009. – № 35 (2). – P. 208–213.
9. Idbaih A. et al. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors // Oncologist. – 2008. – № 13 (9). – P. 978–992.
10. Imyanitov E. N. et al. Partial restoration of degraded DNA from archival paraffinembedded tissues // Biotechniques. – 2001. – № 31 (5). – P. 1000; 1002.
11. Kaatsch P. Epidemiology of childhood cancer // Cancer Treat Rev. – 2010. – № 36 (4). – P. 277– 285.
12. Kaatsch P. et al. Population-based epidemiologic data on brain tumors in German children // Cancer. – 2001. – № 92 (12). – P. 3155–3164.
13. Karajannis M., Allen J. C., Newcomb E. W. Treatment of pediatric brain tumors // J. Cell. Physiol. – 2008.– № 217 (3). – P. 584–589.
14. Knobbe C. B., Reifenberger J., Reifenberger G. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas // ActaNeuropathol. – 2004. – № 108 (6). – P. 467–470.
15. Law M. et al.Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibilityweighted contrastenhanced perfusion MR imaging // Radiology. – 2008. – № 247 (2). – P. 490–498.
16. Louis D. N. et al. The 2007 WHO classification of tumours of the central nervous system // ActaNeuropathol. – 2007. – № 114 (2). – P. 97–109.
17. MacConaill L. E. et al. Profiling critical cancer gene mutations in clinical tumor samples // PLoS One. – 2009. – № 4 (11). – P. e7887.
18. Massimino M. et al. Diffuse pontinegliomas in children: changing strategies, changing results? A mono-institutional 20-year experience // J. Neurooncol. – 2008. – № 87 (3). – P. 3355–3361.
19. Navis A. C. et al. Identification of a novel MET mutation in high-grade glioma resulting in an autoactive intracellular protein // ActaNeuropathol. – 2015. – № 130 (1). – P. 131–144.
20. Onvani S. et al. Molecular genetic analysis of the hepatocyte growth factor/MET signaling pathway in pediatric medulloblastoma // Genes Chromosomes Cancer. – 2012. – № 51 (7). – P. 675–688.
21. Recinos P. F., Sciubba D. M., Jallo G. I. Brainstem tumors: where are we today? // Pediatr. Neurosurg. – 2007. – № 43 (3). – P. 192–201.
22. Reifenberger G., Collins V. P. Pathology and molecular genetics of astrocyticgliomas // J. Mol. Med. – 2004. – № 82 (10). – P. 656–670.
23. Rickert C. H., Paulus W. Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification // Childs Nerv. Syst. – 2001.– № 17(9). – P. 503–511.
24. Sabine V. S. et al. Mutational analysis of PI3K/AKT signaling pathway in tamoxifenexemestane adjuvant multinational pathology study // J. Clin. Oncol. – 2014. – № 32 (27). – P. 2951–2958.
25. Schmidt E. E. et al. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas // Cancer Res. – 1994. – № 54 (24). – P. 6321–6324.
26. Sievert A. J., Fisher M. J. Pediatric low-grade gliomas // J. Child Neurol. – 2009. – № 24 (11). – P. 1397–1408.
27. Thomas R. K. et al. High-throughput oncogene mutation profiling in human cancer // Nat. Genet. – 2007. – № 39 (3). – P. 347–351.
28. Tyner J. W. et al. MET receptor sequence variants R970C and T992I lack transforming capacity // Cancer Res. – 2010. – № 70 (15). – P. 6233–6237.
29. Vogt P. K. et al. Phosphatidylinositol 3-kinase: the oncoprotein // Curr. Top.Microbiol.Immunol. – 2010. – № 347. – P. 79–104.
Review
For citations:
Soltan P.S., Moiseenko F.V., Ochkolyas V.N., Startsev V.Yu. Molecular genetic studies of glial tumors in children. The Scientific Notes of the Pavlov University. 2016;23(4):49-53. (In Russ.) https://doi.org/10.24884/1607-4181-2016-23-4-49-53
Views:
888
Email this article 